10-QPeriod: Q2 FY2026

CVS HEALTH Corp Quarterly Report for Q2 Ended Jun 30, 2026

Filed August 5, 2026For Securities:CVS

Summary

CVS Health Corporation reported strong financial performance for the second quarter and first half of 2026, with total revenues increasing by 7.3% and 6.7% year-over-year, respectively. This growth was driven by robust performance across all operating segments, particularly in 'Products' and 'Services.' The company saw a significant improvement in operating income, which more than doubled year-over-year for the quarter and increased by 63.0% for the first half, largely due to the absence of significant legacy litigation charges recorded in the prior year and improved operating performance across segments. Net income attributable to CVS Health also showed substantial growth, up 191.8% for the quarter and 111.5% for the first half, reflecting the strong operational improvements and a lower effective tax rate. The company maintained a healthy liquidity position with over $11.3 billion in cash and cash equivalents, and operating cash flow significantly improved year-over-year. Despite ongoing litigation and regulatory matters, the company's core business segments demonstrated resilience and growth.

Key Highlights

  • 1Total revenues for the three months ended June 30, 2026, increased by 7.3% to $106.1 billion, and for the six months ended June 30, 2026, by 6.7% to $206.5 billion, compared to the prior year.
  • 2Operating income saw a substantial increase of 97.5% for the quarter ($4.7 billion) and 63.0% for the first half ($9.4 billion), largely driven by the absence of significant legacy litigation charges from the prior year.
  • 3Net income attributable to CVS Health surged by 191.8% to $2.98 billion for the quarter and by 111.5% to $5.92 billion for the first half.
  • 4The effective income tax rate decreased to 24.7% for the quarter and 24.8% for the first half, down from 38.5% and 34.5%, respectively, primarily due to the absence of non-deductible legacy litigation charges.
  • 5Net cash provided by operating activities significantly increased by 64.2% to $10.6 billion for the first half of 2026.
  • 6The Health Care Benefits segment's adjusted operating income grew by 85.5% for the quarter, benefiting from improved underlying performance and the absence of prior year premium deficiency reserves.
  • 7The Health Services segment's adjusted operating income increased by 10.0% for the quarter, driven by improved purchasing economics and pharmacy drug mix.

Frequently Asked Questions

The significant increase in operating income and net income for the three and six months ended June 30, 2026, compared to the prior year, was primarily due to the absence of substantial legacy litigation charges and other one-time expenses (like loss on Accountable Care assets) that were recorded in the prior year. Additionally, improved operating performance across the company's segments contributed to the improved results.

CVS Health demonstrated strong revenue growth. Total revenues for the three months ended June 30, 2026, increased by 7.3% to $106.1 billion, and for the six months ended June 30, 2026, grew by 6.7% to $206.5 billion compared to the same periods in the prior year. This growth was attributed to increases across all operating segments, notably in 'Products' and 'Services'.

As of June 30, 2026, CVS Health maintained a strong liquidity position with $11.3 billion in cash and cash equivalents. The net increase in cash, cash equivalents, and restricted cash for the first six months of 2026 was $2.8 billion, reflecting robust operating cash flows.

Yes, CVS Health is involved in numerous ongoing legal and regulatory proceedings, including those related to PBM practices, controlled substances litigation (opioids), prescription processing, and government program compliance (Medicare/Medicaid). While the company believes its defenses have merit and it has reserves for many matters, some of these could potentially have a material adverse effect on its financial position or results of operations. The company also noted a proposed settlement with the FTC regarding PBM and affiliated pharmacy businesses.